Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina: Proposal for a Multimethod Study

Felder, Tisha M.; Heiney, Sue P.; Hébert, James R.; Friedman, Daniela B.; Elk, Ronit; Franco, Regina; Gansauer, Lucy; Christensen, Barbara L.; Ford, Marvella E.

doi:10.2196/17742

Cited by 5 publications

(5 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The burden of these unaddressed symptoms on BC survivors is further underscored by (1) the long duration of treatment (minimum 5 years) and (2) the high prevalence (roughly 75%) of hormone receptor-positive BC 65 and it should not be underestimated. Quite on the contrary, AHT side-effects should be routinely assessed by health care providers in order to gain a more accurate knowledge that allows a significant improvement in the QoL of the BC survivor undergoing AHT 66 .…”

Section: Discussionmentioning

confidence: 99%

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors

Andreu

Soto‐Rubio

Ramos-Campos

et al. 2022

Sci Rep

View full text Add to dashboard Cite

To explore the modulatory role of Adjuvant Hormone Therapy (AHT) on health-related quality of life (QoL), subjective well-being and distress prevalence in Breast Cancer (BC) survivors, considering the survival phase. Cross-sectional study with control group. 616 BC survivors participated. Examination of interaction effect between AHT and time since end of primary treatment showed that many of the positive changes observed through the survival phases were experienced exclusively by survivors without AHT. When AHT was not prescribed, longer time elapsed was associated with a decrease in distress prevalence and an improvement in subjective well-being and QoL. It seems there is a turning point around the fifth year after finalization of primary treatment, from which the survivors without AHT significantly improve in several areas and those with AHT do so to a lesser extent. It is expected that the improvement in QoL throughout the different survival phases will have a significant impact on the adherence and maintenance of AHT and, consequently, the likelihood of survival. Thus, AHT side-effects should be routinely assessed by health care providers to gain accurate knowledge that allows improving the QoL of BC survivors.

show abstract

Section: Discussionmentioning

confidence: 99%

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors

Andreu

Soto‐Rubio

Ramos-Campos

et al. 2022

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The main reasons for this difference are not clear. The differences in treatment compliance and inherent genetic predisposition may lead to differences in survival between the 2 ethnic groups [32][33][34][35].…”

Section: Discussionmentioning

confidence: 99%

Stage-Specific Survival in Breast Cancer in Chinese and White Women: Comparative Data Analysis

Wang¹,

Zhou²,

Liu³

et al. 2022

JMIR Public Health Surveill

View full text Add to dashboard Cite

Background Stage-specific survival, according to the eighth edition of the American Joint Committee on Cancer (AJCC) pathological prognostic staging (PPS) on breast cancer (BC), between Chinese and White American women remains unclear. Objective This study aimed to assess stage-specific survival in BC between Chinese and White American women according to the eighth AJCC PPS. Methods We included Chinese and White American women with BC diagnosed between 2010 and 2018 from the Surveillance, Epidemiology, and End Results database. A chi-square test, the Kaplan–Meier method, a receiver operating characteristic (ROC) curve, and multivariate Cox proportional hazards models were used for data analysis. Results We included 376,818 individuals in this study: 369,522 White American and 7296 Chinese. Of them, 149,452 (39.7%) migrated from the seventh AJCC anatomic staging (AS) to the eighth AJCC PPS, 22,516 (6.0%) were upstaged, and 126,936 (33.7%) were downstaged. With a median follow-up duration of 44 months, the 5-year overall survival and cancer-specific survival (CSS) for the entire group were 87.4% and 95.9%, respectively. The seventh AJCC AS (P<.001) and the eighth AJCC PPS (P<.001) could significantly predict the survival outcomes of BC, and multivariate analysis revealed that both staging systems were significant prognostic indicators of CSS. The ROC curve revealed that the PPS had a better discriminating ability than the AS (area under the curve [AUC] 0.769 vs 0.753, P<.001). Similar trends were observed after stratification by the 2 ethnic groups. The eighth AJCC PPS had better discriminating ability than the seventh AJCC AS among both White American (AUC 0.769 vs 0.753, P<.001) and Chinese patients (AUC 0.790 vs 0.776, P<.001). In the seventh AJCC AS, Chinese women had better CSS in stage IA (P=.02), stage IIA (P=.005), and stage IIIB (P=.04) disease than White American women, but no significant CSS was observed in stage IB, IIB, IIIA, and IIIC disease between the 2 ethnic groups. Regarding the eighth AJCC PPS, Chinese women had better CSS in stage IA (P=.002) and IIIA (P=.046) disease than White American women, and CSS was similar in Chinese and White American women in other substages. Conclusions The eighth AJCC PPS has a similar discriminative ability between White American and Chinese individuals with BC compared with the seventh AJCC AS. Therefore, the eighth AJCC PPS is also applicable to Chinese individuals with BC.

show abstract

“…These patients are generally prescribed therapy for 5-10 years. Moreover, long-term adherence among disadvantaged populations belonging to low- and low-middle-income countries could result in increased mortality [ 26 ].…”

Section: Reviewmentioning

confidence: 99%

Medication Adherence in Cancer Patients: A Comprehensive Review

Chacko,

Abdulla

et al. 2024

Cureus

View full text Add to dashboard Cite

Cancer is a complex disease that can affect different parts of the body. The rates of cancer have shown an increasing trend in the past decade. A majority of cancers are detected late, therefore becoming untreatable and resulting in significant mortality. Additionally, the lack of awareness about cancers, their risk factors, diagnostic modalities, and preventive measures contributes to increased burden among people. Despite significant developments in the therapeutic and comprehensive management of cancers, the cause for concern is the lack of medication adherence. This is majorly attributed to the adverse effects of the medication, the cost of the drugs, and other reasons. This review comprehensively discusses various aspects of cancer medication adherence that include therapeutic modalities for treating cancers, factors influencing medication adherence, barriers, and facilitators to medication adherence.

show abstract

Improving Adherence to Adjuvant Hormonal Therapy Among Disadvantaged Women Diagnosed with Breast Cancer in South Carolina: Proposal for a Multimethod Study

Cited by 5 publications

References 40 publications

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors

Impact of hormone therapy side effects on health-related quality of life, distress, and well-being of breast cancer survivors

Stage-Specific Survival in Breast Cancer in Chinese and White Women: Comparative Data Analysis

Medication Adherence in Cancer Patients: A Comprehensive Review

Contact Info

Product

Resources

About